[HTML][HTML] Myopic maculopathy: current status and proposal for a new classification and grading system (ATN)

J Ruiz-Medrano, JA Montero, I Flores-Moreno… - Progress in retinal and …, 2019 - Elsevier
Myopia is a highly frequent ocular disorder worldwide and pathologic myopia is the 4th most
common cause of irreversible blindness in developed countries. Pathologic myopia is …

Choroidal neovascularization in pathological myopia

K Neelam, CMG Cheung, K Ohno-Matsui… - Progress in retinal and …, 2012 - Elsevier
Myopic choroidal neovascularization (CNV) is one of the leading causes of visual
impairment worldwide. The clinical and socioeconomic impact of myopic CNV in Asian …

RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia

S Wolf, VJ Balciuniene, G Laganovska, U Menchini… - Ophthalmology, 2014 - Elsevier
Objective To compare the efficacy and safety of ranibizumab 0.5 mg, guided by visual acuity
(VA) stabilization or disease activity criteria, versus verteporfin photodynamic therapy (vPDT) …

Myopic choroidal neovascularization: review, guidance, and consensus statement on management

CMG Cheung, JJ Arnold, FG Holz, KH Park, TYY Lai… - Ophthalmology, 2017 - Elsevier
Topic The aim of this article is to review and compile available information on the
classification, pathophysiology, and clinical features of myopic choroidal neovascularization …

Myopic choroidal neovascularisation: current concepts and update on clinical management

TY Wong, K Ohno-Matsui, N Leveziel… - British Journal of …, 2015 - bjo.bmj.com
Choroidal neovascularisation (CNV) is a common vision-threatening complication of myopia
and pathological myopia. Despite significant advances in understanding the epidemiology …

Myopic maculopathy: a review

R Silva - Ophthalmologica, 2012 - karger.com
Pathological myopia is a major cause of irreversible vision loss and is the fourth to ninth
most frequent cause of blindness in the world. Choroidal neovascularization (CNV) …

Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic …

TYY Lai, FOJ Luk, GKY Lee, DSC Lam - Eye, 2012 - nature.com
Purpose To evaluate the long-term efficacy of intravitreal anti-vascular endothelial growth
factor (anti-VEGF) therapy as primary treatment for subfoveal myopic choroidal …

Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis

E Wang, Y Chen - Retina, 2013 - journals.lww.com
Methods: The authors conducted comprehensive search in PubMed, EMBASE, Cochrane
Library, Biosis Preview, and LILACS. Included studies were categorized by study design …

Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome

JM Ruiz-Moreno, L Arias, JA Montero… - British Journal of …, 2013 - bjo.bmj.com
Objective To report the visual outcome after 4-year follow-up in a series of highly myopic
eyes with choroidal neovascularisation (CNV) treated with antivascular endothelial growth …

Photoreceptor inner segment ellipsoid band integrity on spectral domain optical coherence tomography

S Saxena, K Srivastav, CM Cheung, JYW Ng… - Clinical …, 2014 - Taylor & Francis
Spectral domain optical coherence tomography cross-sectional imaging of the macula has
conventionally been resolved into four bands. However, some doubts were raised regarding …